Detection / Diagnosis
1. Axillary Staging and Sentinel Nodes
2. Biopsy Techniques
3. Circulating Markers
4. Marrow and Blood Micrometastases
5. Diagnostic Pathology
6. Breast Imaging: Mammography
7. Breast Imaging: Other Methods
8. Molecular, Functional, and Novel Imaging
9. Screening and Detection

10. Other

Molecular Basis of Breast Tumorigenesis
11. Angiogenesis
12. Animal Models
13. Apoptosis and Senescence

14. Biomarkers

15. Cell Cycle Regulation

16. Cellular Mechanisms

17. DNA Damage and Repair

18. Drug Resistance

19. Endocrine Therapy and Resistance

20. Epigenetics

21. Etiology/Carcinogenesis

22. Gene Therapy

23. Genetics/Germline Changes

24. Genetics/Somatic Changes

25. Genomics

26. Growth Factors

27. Hormonal Factors and Receptors

28. Immunology and Immunotherapy

29. Metabolism and Breast Cancer

30. Tumor Microenvironment

31. Molecular Profiles

32. Novel / Emerging Therapeutic Targets

33. Novel Models

34. Oncogenes / Tumor Suppressor Genes

35. Stem / Progenitor Cells

36. Stromal-Epithelial Interactions

37. Systems Biology of Breast Cancer

38. Telomeres and Telomerase

39. Tumor Heterogeneity / Molecular Subclassification

40. Tumor Progression, Invasion, and Metastasis

41. Virology

42. Other

Prognosis and Response Predictions
43. Biomarkers - Methods
44.Response Predictions - Biomarkers and Other Factors
45. Prognostic Factors and Biomarkers - Preclinical

46. Prognostic Factors and Biomarkers - Clinical Testing and Validation

47. Other

Risk, Epidemiology, and Prevention
48. Epidemiology - Population Studies

49. Epidemiology -Genetic and Molecular
50. Ethnic/Racial Aspects
51. Familial Breast Cancer - Genetic Testing

52. Familial Breast Cancer - Molecular Genetics

53. Prevention - Behavioral Interventions

54. Prevention - Nutritional Studies

55. Prevention - Clinical Trials

56. Prevention - Preclinical Studies and Model Systems

57. Risk Factors and Modeling

58. Stress / Hypoxia

59. Other

Social, Behavioral, Economic, and Outreach Studies
60. Advocacy
61. Cost Effectiveness

62. Disparities and Barriers to Care

63. Doctor-Patient Communication

64. Education

65. Palliation and Support (Pain Management)

66. Psychosocial Aspects

67. Quality of Life - Supportive Care

68. Survivorship Research

69. Other

Treatment
70. Adjuvant Chemotherapy

71. Adjuvant Endocrine Therapy

72. Adjuvant Therapy - Targeted

73. Adjuvant Therapy - Other

74. Neoadjuvant Therapy

75. Advanced Chemotherapy

76. Advanced Endocrine Therapy

77. Advanced Therapy - Targeted

78. Advanced Therapy - Other

79. Alternative Therapies

80. Antiangiogenic Therapy (Adjuvant and Metastatic)

81. Antibody-Based Regimens

82. Biological Therapy

83. Signal Transduction Inhibitors

84. Novel Targets and Targeted Agents

85. Her2-Targeted Therapy (Adjuvant and Metastatic)

86. New Drugs and Treatment Strategies

87. Managing Therapy-Related Toxicities

88. Bone Metastases

89. DCIS / LCIS

90. Male Breast Cancer

91. Radiation Therapy

92. Surgery

93. Breast Conservation

94. Other

Preparation

• The abstract must be in English.
  
• Any author who, for religious reasons, cannot present on a particular day of the week, must enclose written notification with the submitted abstract.

Submission

• When finished with your online submission, be sure to click the "Submit" button.  Abstracts received without a properly completed Disclosure/Attestation absolutely will not be considered.  The size limit for the abstract (including authors, institutions, title, body, tables and figures) is 3400 characters (including spaces).
  
• Abstracts are due by 11:59 CDT on June 16, 2008.